Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant. - Archive ouverte HAL Access content directly
Journal Articles Drug Discovery Today Year : 2009

Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.

(1) , (1) , (1)
1

Abstract

Obesity, currently associated with metabolic syndrome is characterized by an excessive fat storage in different organs, in particular adipose tissue, inducing the loss of its structural and functional integrity. Being aware of the importance of adipose tissue endocrine function and the key role of adipocytokines, such as adiponectin, in obesity and metabolic syndrome drives the necessity to develop new drugs that can exert a specific action on adipose tissue and on adiponectin levels. Rimonabant, an antiobesity drug, presents a dual effect by decreasing food intake and importantly increasing adiponectin. This review focuses on the key role of adiponectin regulation in the success of rimonabant and suggests that this adipohormone may be considered as a therapeutic target to design innovative and promising antiobesity and anti-metabolic syndrome drugs.
Fichier principal
Vignette du fichier
Gary-Bobo_Manuscript.pdf (183.17 Ko) Télécharger le fichier
Vignette du fichier
Gary-Bobo_Figure1.ppt (62.5 Ko) Télécharger le fichier
Vignette du fichier
Gary-Bobo_Figure2.ppt (182.5 Ko) Télécharger le fichier
Vignette du fichier
inserm-00338419_edited.pdf (411.27 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Format : Other
Format : Other
Origin : Files produced by the author(s)

Dates and versions

inserm-00338419 , version 1 (13-11-2008)

Identifiers

Cite

Marie Maynadier, Ilaria Basile, Magali Gary-Bobo. Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.. Drug Discovery Today, 2009, 14 (3-4), pp.192-7. ⟨10.1016/j.drudis.2008.09.009⟩. ⟨inserm-00338419⟩
323 View
1011 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More